ORAGENICS INC

NYSE:OGEN

Pharmaceutical Preparations·LAKEWOOD RANCH, FL

CEO

Huffman Janet

Summary Financials

Revenue

$37,653

-71.4% YoY

FY 2024

Adj. EBITDA

-$20.9M

-55406.4% margin

FY 2024

Net Income

-$20.7M

-54858.1% margin

FY 2024

EPS (Diluted)

-$9.18

FY 2024

Stock Price

$0.90

+1.3%

2026-03-06

52W Range

$0.61 – $9.60

P/E Ratio

-0.1x

Market Cap

$3.8M

Cash

$3.5M

FY 2024

Total Debt

$312,703

FY 2024

Net Cash

$3.2M

FY 2024

Enterprise Value

$580,185.878

Debt / EBITDA

0.2x

FY 2024

EV / EBITDA

-0.0x

Employees

—

Revenue

$37,653

-71.4% YoY

FY 2024

Adj. EBITDA

-$20.9M

-55406.4% margin

FY 2024

Net Income

-$20.7M

-54858.1% margin

FY 2024

EPS (Diluted)

-$9.18

FY 2024

Stock Price

$0.90

+1.3%

2026-03-06

52W Range

$0.61 – $9.60

P/E Ratio

-0.1x

Market Cap

$3.8M

Cash

$3.5M

FY 2024

Total Debt

$312,703

FY 2024

Net Cash

$3.2M

FY 2024

Enterprise Value

$580,185.878

Debt / EBITDA

0.2x

FY 2024

EV / EBITDA

-0.0x

Employees

—